SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency

66Citations
Citations of this article
64Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Current genetic evidence in mice indicates that SIRT1 has potent tumor suppressor activity in a variety of cancer models, with no evidence yet for SIRT1 oncogenic activity in vivo. We report here that transgenic Sirt1 expression is oncogenic in murine thyroid and prostate carcinogenesis initiated by Pten-deficiency. Based on mRNA expression analyses of pre-tumoral murine thyroids, we find that SIRT1 increases c-MYC transcriptional programs. Moreover, we show higher c-MYC protein levels in murine thyroid cancers from Sirt1 transgenic mice. Similarly, SIRT1 is overexpressed in human thyroid cancers and it is positively correlated with c-MYC protein levels. Finally, we show in cultured thyroid cancer cells that SIRT1 stabilizes c-MYC protein. These results implicate SIRT1 as a new candidate target for the treatment of thyroid carcinomas. © 2013 Macmillan Publishers Limited All rights reserved.

Cite

CITATION STYLE

APA

Herranz, D., Maraver, A., Cañamero, M., Gómez-López, G., Inglada-Pérez, L., Robledo, M., … Serrano, M. (2013). SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency. Oncogene, 32(34), 4052–4056. https://doi.org/10.1038/onc.2012.407

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free